Drugs / Allergen extract
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02665754 | Jul 2016 → Dec 2019 | allergic rhinitis | Gachon University Gil Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02301884 | Nov 2013 → Dec 2014 | allergic rhinitis | Gachon University Gil Medical Center | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01012882 | Nov 2016 → Nov 2017 | seasonal allergic rhinitis | Roxall | Unknown | No outcome recorded |
| Phase 3 | NCT01014325 | Sep 2016 → Sep 2017 | allergic rhinitis | Roxall | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allergen extract | “0.5 ml of allergen extract from D. farinae, D. pteronyssinus, cat, and/or dog for allergen specific immunotherapy (Tyrosine S, Allergy Therapeutic, UK) will be injected into...” NCT02665754 ↗ |
| Known as | Tyrosine S | “0.5 ml of allergen extract from D. farinae, D. pteronyssinus, cat, and/or dog for allergen specific immunotherapy (Tyrosine S, Allergy Therapeutic, UK) will be injected into...” NCT02665754 ↗ |
| Route | Other | “Intralymphatic injection in volume of 0.1 ml, three times with 4-week interval” NCT02301884 ↗ |